Elizabeth Gillies, Ph.D.,
Scientist, ATCC Cell Systems
Dr. Elizabeth Gillies is a scientist with ATCC Cell Systems. She has been using CRISPR/Cas9 genome editing to create cell-based models of human disease since the development of the technology in 2013. Dr. Gillies’ doctoral work focused on the generation and study of isogenic cell lines that recapitulate the cellular phenotypes of diseases of the nuclear envelope, which are associated with congenital conditions such as Torsin dystonia, Pelger-Huët anomaly, and Greenberg skeletal dysplasia. She obtained her Ph.D. in Molecular Biophysics and Biochemistry from Yale University in 2015 and joined ATCC shortly thereafter.